Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation (ASAPF) generates a steady stream of news around its spinal implant platforms, biologics portfolio, and participation in medical and investor events. The company’s releases highlight developments in minimally invasive spine surgery, interventional pain management, and bone density–matched implant technology.
Recent announcements emphasize Aurora Spine’s DEXA Technology platform, including the DEXA-C cervical fusion system and the DEXA-L anterior lumbar interbody fusion device, which the company describes as bone-mimicking implants engineered to match a patient’s bone density and quality. Other news focuses on the SiLO Sacroiliac Joint Fusion System, which Aurora reports has been used in more than 2,500 procedures, and the AERO Lumbar Fusion System, a minimally invasive facet fusion device cleared for use from C2 to S1.
Investors and clinicians following ASAPF news will also see updates on Aurora Biologics, a division dedicated to allograft-based biologic solutions designed to support spinal fusion and work in concert with the company’s mechanical implants. Patent issuances, such as those covering the ZIP implant family and bone density scan–matched orthopedic implants, further illustrate Aurora’s focus on intellectual property around spinal implant design.
This news feed captures product launches, clinical usage milestones, conference participation at meetings like NASS and ASPN, and scheduled financial result releases and investor presentations. Users can monitor these updates to understand how Aurora Spine presents the evolution of its spine technologies, surgeon adoption, and broader corporate activities over time.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the 2024 North American Spine Society (NASS) Annual Meeting from September 25-28, 2024, at McCormick Place, Chicago. The company will showcase its latest innovations at Booth #4510, including:
- SiLO™ TFX SI Fusion System for sacroiliac joint fusion surgery
- DEXA-C cervical interbody cage system with patented DEXA™ Technology
- Hydra™ and OSTEO-ONYX™ lumbar fusion systems with Rough Surface Technology (RST)
- ZIP-51® Interlaminar Fusion System for minimally invasive L5/S1 fusion
Aurora Spine's executives emphasize the transformative nature of their products, particularly highlighting the DEXA-C implant line as the world's first patient-matched interbody implant system.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) announces a recorded ZOOM call on September 13, 2024, featuring CEO Trent Northcutt and Alpha Wolf Trading CEO Tim Weintraut. The call will highlight Aurora's latest innovations and financial success, including:
1. DEXA™ Technology: Patient-specific interbody implants
2. New Product Launches: Hydra and Osteo-Onyx Lumbar Screw Systems
3. ZIP™ Multi-Center Study Results
4. SiLO™ TFX SI Joint Fusion System: Fastest-growing product
Financial highlights include:
- Q2 2024 EBITDAC: $105,522
- Q2 2024 sales: $4,079,543 (14.3% increase)
- Q2 gross margin: 62.4%
- SiLO™ sales: $1.7 million (41.7% of Q2 revenue)
- ZIP™ 51 sales doubled to $669,316
Aurora continues to expand its sales force and host advanced training sessions for physicians.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the Latin America Pain Society (LAPS) Annual Congress from September 5-7, 2024, in Mexico City. The company, which specializes in designing and manufacturing innovative medical devices for spinal surgery, will showcase its latest advancements in minimally invasive spinal devices and pain management solutions.
The LAPS conference provides Aurora Spine with a platform to present technologies aimed at optimizing patient care, reducing recovery times, and improving quality of life. The event brings together nationally and internationally renowned experts in pain management, offering opportunities for knowledge sharing and peer interaction. Matt Goldstone, Chief Commercial Officer of Aurora Spine, expressed excitement about participating in the conference and showcasing the company's cutting-edge advances and state-of-the-art technologies for better patient care.
Aurora Spine (OTCQB: ASAPF), a developer of innovative spinal surgery devices, will participate in the Sixth Annual American Society of Pain & Neuroscience (ASPN) Conference from July 11-14, 2024, in Miami Beach, Florida. Aurora will showcase its products at Booth 121 and host a product theater on July 12th at 10:15 a.m.
During the event, prominent physicians Dr. Pankaj Mehta, Dr. Steven Falowski, and Dr. Jason Pope will present findings from Aurora Spine’s Refine Study. This study is the first multi-center, multi-specialty, randomized control trial focusing on interlaminar fusion, comparing Aurora’s SILO TFX and ZIP 51 devices. Aurora's President and CEO, Trent Northcutt, expressed enthusiasm for the opportunity to present their cutting-edge products and clinical results to leading physicians.
Aurora Spine has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results. The call will take place on May 14, 2024, at 11:00 a.m. Eastern Time. Interested parties can access the call via dial-in or webcast. A replay will be available for a time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.